

Hemorrhagic Problem Among the Patients With COVID-19: Clinical Summary of 41 Thai Infected Patients

Clinical and Applied
Thrombosis/Hemostasis
Volume 26: 1
© The Author(s) 2020
Article reuse guidelines:
sagepub.com/journals-permissions
DOI: 10.1177/1076029620918308
journals.sagepub.com/home/cat



Beuy Joob, PhD¹ , and Viroj Wiwanitkit, MD²

Date received: 22 January 2020; revised: 06 March 2020; accepted: 18 March 2020.

In late December 2019, a new emerging infectious disease, coronavirus disease 2019 (COVID-19), started in China.¹ The disease already spread to more than 40 countries at present (February 29, 2020). Thailand is the second country that was affected by this new disease.² Focusing on clinical presentation of this new coronavirus infection, the main clinical presentation is acute febrile illness with pulmonary complications.

In clinical hematology, the effect of the infection is reported. Leukopenia is a common clinical blood picture.^{3,4} Regarding the alteration of coagulation system, decreased platelet count and prothrombin time is observable.^{3,4} In fact, this is similar observation to that seen in a previous emerging coronavirus infection, Middle East respiratory syndrome.⁵ Nevertheless, there is still no report regarding hemorrhagic problem in the patients with COVID-19. Here, the authors would like to present observation from Thailand on 41 patients (4 males and 37 females, age between 7 and 74 years) with COVID-19 in Thailand (based on most update data at February 29, 2020). The diagnosis of COVID-19 was done by real-time polymerase chain reaction molecular diagnosis and reconfirmed for positive by 2 referencing molecular diagnosis laboratory. All presented with febrile illness and pneumonia within 14 days after history of exposure and the direct human to human contact is mode of transmission. Of these patients, there is no death case (at present, 28 are discharged after complete recovery from illness and 13 are still hospitalized). All of these patients received standard respiratory care in isolate clinical pulmonary unit. Of interest, there is a patient (2.44%) with bleeding presentation, petechiae. For this case, there is no specific additional treatment for hemorrhagic problem. This patient was firstly missed diagnosed to be dengue and cause local transmission to a medical worker.⁶ It is recommended that the

practitioner should recognize that hemorrhagic problem might be an initial presentation of COVID-19. Also, investigation and follow-up for possible hemorrhagic problem in patient with COVID-19 is recommended.

Authors' Note

Viroj Wiwanitkit is a visiting professor at the Hainan Medical University, Haikou, China.

ORCID iD

Beuy Joob  <https://orcid.org/0000-0002-5281-0369>

References

1. Hsia W. Emerging new coronavirus infection in Wuhan, China: situation in early 2020. *Case Study Case Rep.* 2020;10(3):8-9.
2. Yasri S, Wiwanitkit V. Editorial: Wuhan coronavirus outbreak and imported case. *Adv Trop Med Pub Health Int.* 2019;9(2):1-2.
3. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet.* 2020;395(10223):507-513.
4. Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China [published online February 7, 2020]. *JAMA.* 2020. doi:10.1001/jama.2020.1585.
5. Joob B, Wiwanitkit V. Magnitude to thrombocytopenia among the patients with novel Middle East respiratory syndrome. *Platelets.* 2015;26(6):612.
6. Joob B, Wiwanitkit V. COVID-19 in medical personnel: observation from Thailand. *J Hosp Infect.* 2020. (In Press). <https://doi.org/10.1016/j.jhin.2020.02.016>.

¹ Medical Academic Center, Bangkok, Thailand

² DY Patil University, Pune, India

Corresponding Author:

Beuy Joob, Medical Academic Center, Bangkok, Thailand.
Email: beuyjoob@hotmail.com



Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (<https://creativecommons.org/licenses/by-nc/4.0/>) which permits non-commercial use,

reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (<https://us.sagepub.com/en-us/nam/open-access-at-sage>).